Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OKUR
SellHot AirOnKure Therapeutics, Inc. · Healthcare · United States · $153M · Avg Vol: $499K/d
26
StockRankGet insider-trade alerts
Q
29
V
35
M
51
P/E (TTM)
—
ROE
-46.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 0.3M | 0.7M | — |
| EPS | -0.73 | -0.87 | -5.05 | -1.49 | — | -3.03 | -1.83 | -1.53 | — |
| Shares | 40.4M | 40.4M | 40.4M | 40.4M | 0.0% | 40.5M | — | — | — |
| Debt | 0.6M | 0.7M | 1.1M | 0.5M | -4.8% | 0.9M | — | — | — |
| Equity | -54.4M | -101.8M | 103.8M | 56.2M | -45.9% | — | — | — | — |
| Op CF | -27.0M | -34.5M | -51.1M | -51.8M | — | -47.8M | — | — | — |
| Inv CF | -1.1M | -0.2M | 15.9M | -46.0K | — | — | — | — | — |
| Fin CF | 26.5M | 53.1M | 116.1M | 0.2M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-18.3%
SMA 50SMA 200
Close
$3.27
RSI (14)
9.8
52W High
$5.38
From 52W High
0.6%
SCORE BREAKDOWN
Quality
29
ROIC
-105.3%6.1
ROE
-46.9%19.3
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-81.8%3.1
Piotroski
321.9
Int. Cover
-50.0x5.9
D/E Ratio
0.01x88.6
Current Ratio
26.75x97.6
Value
35
P/E (TTM)
—N/A
EV/EBITDA
0.5x25.0
P/FCF
—N/A
P/B
0.8x90.0
P/S
—N/A
Div Yield
—N/A
Momentum
51
52W High %
61%37.9
RS 6M
-20%40.9
SMA 50/200
1.09x74.7
EPS Rev 4W
+28.3%96.2
EPS Rev 12W
—N/A
EPS Improve
+50%54.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$153M
P/E (Forward)
-2.3x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OKUR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OKUR | OnKure Therapeutics, Inc.(you) | $153M | 26 | Sell |
| EQ | Equillium, Inc. | $152M | 27 | Sell |
| NRXP | NRx Pharmaceuticals, Inc. | $154M | 23 | Sell |
| IMUX | Immunic, Inc. | $210M | 26 | Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 22 | Sell |
| CDXS | Codexis, Inc. | $174M | 21 | Sell |
| DTIL | Precision BioSciences, Inc. | $215M | 28 | Sell |
| SEER | Seer, Inc. | $110M | 28 | Sell |
| NKTX | Nkarta, Inc. | $198M | 22 | Sell |
| PTHS | Pelthos Therapeutics Inc. | $95M | 26 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%